Stephen Lam Chan, MBBS, Chinese University of Hong Kong, Hong Kong, China, discusses the current treatment landscape and possible future directions in terms of combination approaches for hepatocellular carcinoma (HCC). Several Phase III clinical trial have shown the combination of anti-PD-1 or PD-L1 with anti-CTLA-4 is associated with an improvement in overall-survival (OS) in the first-line setting, suggesting future first-line treatment options to be a combination of immunotherapies. Data has demonstrated the efficacy of the multi-kinase inhibition in the second-line setting, particularly with lenvatinib or cabozantinib. Additionally, studies have suggested approximately 40-50% of patients can receive treatment up to the third-line setting. Maximizing the patients chance of receiving further lines of treatment and preserving pelvic function prior to liver failure so they are able to receive systemic therapy is a future key research area. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.